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Gleason grading of prostate cancer is an important prognostic factor but suffers from poor 
reproducibility, particularly among non-subspecialist pathologists.1–7 Although artificial 
intelligence (A.I.) tools have demonstrated Gleason grading on-par with expert pathologists,8–12 
it remains an open question whether A.I. grading translates to better prognostication. In this 
study, we developed a system to predict prostate-cancer specific mortality via A.I.-based 
Gleason grading and subsequently evaluated its ability to risk-stratify patients on an 
independent retrospective cohort of 2,807 prostatectomy cases from a single European center 
with 5-25 years of follow-up (median: 13, interquartile range 9-17). The A.I.’s risk scores 
produced a C-index of 0.84 (95%CI 0.80-0.87) for prostate cancer-specific mortality. Upon 
discretizing these risk scores into risk groups analogous to pathologist Grade Groups (GG), the 
A.I. had a C-index of 0.82 (95%CI 0.78-0.85). On the subset of cases with a GG in the original 
pathology report (n=1,517), the A.I.’s C-indices were 0.87 and 0.85 for continuous and discrete 
grading, respectively, compared to 0.79 (95%CI 0.71-0.86) for GG obtained from the reports. 
These represent improvements of 0.08 (95%CI 0.01-0.15) and 0.07 (95%CI 0.00-0.14) 
respectively. Our results suggest that A.I.-based Gleason grading can lead to effective risk-





Prostate cancer affects 1 in 9 men in their lifetime13 but disease aggressiveness and prognosis 
can vary substantially among individuals. The histological growth patterns of the tumor, as 
characterized by the Gleason grading system, are a major determinant of disease progression 
and criterion for selection of therapy. Based on the prevalence of these patterns, one of five 
Grade Groups (GG) is assigned.14 The GG is among the most important prognostic factors for 
prostate cancer patients, and is used to help select the treatment plan most appropriate for a 
patient’s risk of disease progression.15 
 
The Gleason system is used at distinct points in the clinical management of prostate cancer. For 
patients undergoing diagnostic biopsies, if tumor is identified, the GG impacts the decision 
between active surveillance versus definitive treatment options such as surgical removal of the 
prostate or radiation therapy.15 For patients who subsequently undergo a surgical resection of 
the prostate (radical prostatectomy), the GG is one key component of decisions regarding 
adjuvant treatment such as radiotherapy or hormone therapy.16,17 In large clinical trials, use of 
adjuvant therapy following prostatectomy has demonstrated benefits such as improved 
progression-free survival for some patients, but can also result in substantial adverse side 
effects18–20.  As such, several post-prostatectomy nomograms21 have been developed in order 
to better predict clinical outcomes following definitive treatment, with the goal of identifying the 
patients most likely to benefit from adjuvant therapy. Gleason grading of prostatectomy 
specimens represents a key prognostic element in many of these nomograms and is a central 
component of the risk categories defined by the National Comprehensive Cancer Network17.  
 
Due to the complexity and intrinsic subjectivity of the system, Gleason grading suffers from 
large discordance rates between pathologists (30-50%)1–6. However, grades from experts (such 
as those with several years of experience, primarily practicing urologic pathology or those with 
urologic subspeciality training) are more consistent and result in more accurate risk stratification 
than grades from less experienced pathologists7,22–24, suggesting an opportunity to improve the 
clinical utility of the system by improving grading consistency and accuracy. To this end, several 
artificial intelligence (A.I.) algorithms for Gleason grading have been developed and validated 
using expert-provided Gleason scores.9–12 However, an evaluation of the prognostic value of 
these algorithms and a direct comparison to the prognostic value of Gleason grading provided 
by pathologists has not been conducted. While the GG for biopsies as well as prostatectomy 
specimens both provide important prognostic information14, retrospective studies to evaluate 
long-term clinical outcomes is more straightforward from prostatectomy cases given widely 
divergent treatment pathways following biopsy alone. 
 
Building on prior work8,10, we first trained an A.I. system to accurately classify and quantitate 
Gleason patterns on prostatectomy specimens, and further demonstrate that A.I.-based 
Gleason pattern quantitations can be used to provide better risk stratification than the Gleason 




All archived slides in prostatectomy cases from 1995-2014 at the Biobank at the Medical 
University of Graz in Austria25 were digitized. After excluding 9 cases for death within 30 days of 
surgery and 8 cases without evidence of prostate cancer in the resection, 2,807 cases remained 
(Supplementary Figure S1). The median follow-up time was 13.1 years (interquartile range 8.5-
17.2). These cases were grouped into two validations sets: all cases (validation set 1) and the 
subset of cases from 2000-2014 for which Gleason grading was performed at the time of 
pathologic diagnosis and provided in the final pathology report  (n=1,517 cases, validation set 
2). Descriptive statistics for both validation sets are provided in Table 1. 
 
For each case, the A.I. algorithm assessed the tumor composition and output percentages for 
the 3 different Gleason patterns (%GP3, %GP4, %GP5). We fit a Cox proportional hazards 
regression model directly on these percentages to produce continuous A.I. risk scores, using 
leave-one-out-cross-validation to “adjust for optimism”14. On validation set 1, this continuous A.I. 
risk score achieved a C-index of 0.84 (95%CI 0.80-0.87) (Table 2). In pre-specified primary 
analysis, on validation set 2, the C-index for the A.I. risk score (0.87) was significantly greater 
than the C-index for the GG obtained from the original pathology report (0.79), an improvement 
of 0.08 (95%CI 0.01-0.15). 
 
To provide an additional comparison to pathologists’ GG categorizations, we discretized the A.I. 
risk scores into five “A.I. risk groups” such that the number of cases per risk group matched the 
number of cases in the corresponding GG. Similar to the A.I. risk score, the C-index for the A.I. 
risk groups (0.85) was also greater than the C-index for the pathologist GG (Table 2), an 
improvement of 0.07 (95%CI 0.00-0.14). Furthermore, Kaplan-Meier analyses showed 
significant risk stratification across A.I. risk groups across both validation sets (p<0.001 for log-
rank test, Figure 1) and univariable Cox regression analyses showed higher hazard ratios for 
higher A.I. risk groups (Supplementary Table S1). 
 
We also evaluated the prognostic performance of the A.I. in the context of the pathologic T-
category. Kaplan-Meier analyses showed significant risk stratification across A.I. risk groups 
even within groups defined by high and low T-category (p<0.001 for log-rank test, 
Supplementary Figure S2B). Furthermore, using the A.I. risk groups in a multivariable Cox 
model that also included T-category gave a C-index that trended higher than using the 
pathology-report derived Grade Groups (Supplementary Figure S2A). 
 
To better understand discordances between the A.I. risk groups and pathologist GG, we first 
compared 10-year disease-specific survival rates for cases where the A.I. risk group was higher 
or lower than the pathologist GG (Supplementary Table S3). Within each pathologist-
determined GG, the 10-year survival rates were higher for cases where the A.I. provided a lower 
risk classification, especially for GG ≥ 3. The survival rates also tended to be lower where the 
A.I. provided a higher risk classification. Second, risk stratification by the A.I.’s risk groups 1-2 
vs. 3-5 remained significant within each pathologist-determined GG (Figure 2). In particular, 
 
 
among patients with pathologist GG 3-5, a sizable subgroup (181 of 436, 42%) were assigned 
A.I. risk groups of 1-2 and these patients did not experience any disease-specific mortality 
events (Supplementary Table S3, Figure 2). 
 
Finally, we explored the potential benefit of combining the A.I. system and pathologist grading 
by evaluating an “ensembling” approach. The arithmetic mean of the A.I. risk group and 
pathologist-provided GG resulted in a C-index of 0.86 (95%CI 0.80-91) vs. 0.79 for pathologists 
and 0.85 for the A.I. risk groups (Supplementary Figure S2A). Furthermore, qualitative analysis 
of algorithm and pathologist discordances suggests several ways in which the algorithmic 
grading and pathologist grading may be complementary, including consistent grading of regions 
by the AI which may be variably overgraded by pathologists, or identification of small, high 
grade regions which may otherwise be missed by pathologists.     
Discussion 
In this study, we have validated the ability of a Gleason grading A.I. system to risk-stratify 
patients using an independent dataset of over 2,800 prostatectomy cases with a median of 13 
years of follow-up. The A.I. system demonstrated highly effective risk stratification and, in pre-
specified primary analysis, provided significantly better risk stratification than GGs obtained from 
the original pathology reports. 
 
After prostatectomy, adjuvant radiotherapy for patients with high-risk pathological features has 
been shown to reduce rates of disease recurrence in multiple clinical trials18–20, and to improve 
overall survival in some cohorts26. Given their prognostic value, Gleason grades represent a key 
factor in adjuvant therapy decisions, with NCCN practice guidelines suggesting higher risk 
patients be considered for adjuvant therapy15. However, use of adjuvant radiotherapy can cause 
adverse effects, contributing to low utilization of this treatment option27 despite there being a 
subset of patients who would likely benefit. While risk stratification tools such as nomograms (in 
which the Gleason Score is among the most prognostic factors)21 and molecular tests28 have 
been developed, selection of patients for adjuvant therapy post prostatectomy remains a difficult 
task15. Given the ability of the A.I. to provide significant risk stratification among patients most 
likely to consider adjuvant therapy (GG 3-5 and pT3 and above, Supplementary Figure S2C), 
our results suggest that the A.I. risk-score could be particularly useful for informing adjuvant 
therapy decisions. Evaluation of whether additional prognostic value can be obtained by 
combining the A.I. risk score with existing prognostic tools such as nomograms and molecular 
approaches is also warranted. 
 
The A.I. system may also contribute to clinical decision making by directly assisting pathologist 
grading as a computer-aided diagnostic (CADx) tool. Prior work has shown that a CADx tool for 
Gleason grading can improve grading consistency and accuracy by pathologists, with 
pathologists benefiting from the consistent grading provided by the A.I. while also correcting and 
overriding unexpected A.I. errors as needed29,30. Given the prognostic importance of expertise in 
pathology review7, and the scarcity of specialty pathologists in low-income and middle-income 
countries31,  utilization of the A.I. system as an assistive tool during prostatectomy review has 
 
 
the potential to improve access to consistent, accurate grading, and may ultimately result in 
grading that more accurately predicts patient outcome.   
 
While not directly comparable due to differences in cohorts and study design, the prognostic 
performance observed for the pathologist Gleason grading in this cohort is largely consistent 
with prior work evaluating associations of pathologist grading and clinical outcomes (c-indices of 
0.70-0.83 for Grade Groups and biochemical recurrence14,32,33 and 0.80 for the recent STAR-
CAP clinical prognostic grouping and DSS34). 
 
Several other works have developed Gleason grading algorithms, though without validating 
them on clinical outcomes9,11,35. Additionally, Yamamoto et al. recently demonstrated the ability 
to directly learn prognostic histologic features in prostate cancer specimens that correlate with 
patient outcomes36. The present study complements prior work by building upon an extensively 
validated Gleason system to provide A.I. risk assessments that are directly interpretable by 
pathologists and utilizing a large independent dataset with long-term clinical follow-up for direct 
validation of these assessments on patient outcomes.   
 
This study has some limitations. First, without access to treatment information for this cohort, we 
were unable to evaluate our A.I. within subgroups defined by potentially different treatment 
pathways following prostatectomy. Next, the Gleason grading system has evolved over the time 
period in which data was collected for this study, potentially contributing to inconsistencies in 
grading between pathologists and underestimating the prognostic performance of the GG in the 
original report. Relatedly, we did not have access to the raw Gleason pattern percentages used 
by pathologists to determine the Grade Group, which limited comparison with continuous 
pathologist risk scores. Similarly, the A.I. does not take into account grading subtleties such as 
grading dominant or codominant nodules, but evaluates the entire case holistically. Next, this 
study focuses on prostatectomy specimens. The benefit of prostatectomy-based analysis is that 
the interpretation of prognostication performance in resections is more straightforward than for 
biopsies due to less divergent post-operative treatment pathways37. Future work to validate an 
accurate A.I. system’s prognostic utility on biopsies may provide additional opportunities to 
inform and improve post-biopsy clinical decisions. Lastly, in addition to Gleason grading, 
pathologists review cases for additional criteria, including TNM staging, cancer variants38, and 
other pathologic findings not evaluated by our system. Therefore, the potential benefits of 
integrating our A.I. system into a routine pathology workflow will ultimately need to be evaluated 
in prospective studies.  
 
To conclude, we have validated the ability of an A.I. Gleason grading system to effectively risk-
stratify patients on a large retrospective cohort, outperforming the Gleason GG in the original 
report. We look forward to future research involving the clinical integration and evaluation of the 





All available slides for archived prostate cancer resection cases between 1995 and 2014 in the 
Biobank Graz at the Medical University of Graz were retrieved, de-identified, and scanned using 
a Leica Aperio AT2 scanner at 40X magnification (0.25 μm/pixel). Primary and secondary 
Gleason patterns (Gleason Scores)  were extracted from the original pathology reports, along 
with pathologic TNM staging, and patient age at diagnosis.  Gleason Scores were translated to 
their corresponding Grade Groups14. 22 cases (1%) were indicated as having pathologic T-
category in T1 in the original pathology report, which is a categorization reserved for clinical T-
category only; these pathology reports were subsequently re-reviewed by a pathologist for 
appropriate re-categorization. Disease-specific survival (DSS) was inferred from International 
Classification of Diseases (ICD) codes from the Statistik Austria database. Codes considered 
for prostate-cancer related death were C61 and C68. Institutional Review Board approval for 
this retrospective study using anonymized slides and associated pathologic and clinical data 
was obtained from the Medical University of Graz (Protocol no. 32-026 ex 19/20). 
 
Validation set 1 included all available cases from 1995-2014 after application of the exclusion 
criteria (n=2,807, Table 1 and Supplementary Figure S1). Because Gleason scoring at the 
Medical University of Graz was adopted in routine practice from 2000 onwards, validation set 2 
included all cases from 2000 onwards for which a Gleason score was available (n=1,517, Table 
1). Sensitivity analysis for inclusion of Gleason grades prior to the year 2000 (before Gleason 
scoring became routine at the institution) is presented in Supplementary Table S4.  
 
All slides underwent manual review by pathologists (See “Pathologist Cohort” in the 
Supplementary Methods) to confirm stain type and tissue type. Inclusion/exclusion criteria are 
described in Supplementary Figure S1. Briefly, immunohistochemically stained slides were 
excluded from analysis and only slides containing primarily prostatic tissue were included. 
Slides containing exclusively prostatic tissue were included in their entirety. Slides with both 
prostatic tissue and seminal vesicle tissue were included, but processed using a prostatic tissue 
model meant to provide only prostatic tissue to the Gleason grading model (see “Prostatic 
Tissue Segmentation Model” in Supplementary Methods).  
Gleason Grading Model 
We previously developed two A.I. systems: one for Gleason grading prostatectomy specimens8 
based on a classic “Inception” neural network architecture, and a second for Gleason grading 
biopsy specimens based on a customized neural network architecture10. For this work, we used 
the prostatectomy dataset from the first study to train a new model using the customized neural 
network architecture introduced in the second study. The training dataset contained 112 million 
pathologist-annotated “image patches” from a completely independent set of prostatectomy 
cases from the validation data used in this study. Briefly, the system takes as input 512x512 
 
 
pixel image patches (at 10X magnification, 1 μm per pixel) and classifies each patch as one of 
four categories: non-tumor, Gleason pattern 3, 4, or 5. The hyperparameters used for training 
this network were determined using a random grid search over 50 potential settings and are 
described in Supplementary Table S6.  
A.I. Risk Scores and Risk Groups 
The Gleason grading model was run at stride 256 (at 10X magnification, 1 μm per pixel) on all 
prostate tissue patches. The classification of each patch as non-tumor or GP 3, 4, or 5 was 
determined via argmax on re-weighted predicted class probabilities8. For each case, the 
percentage of prostate tumor patches that belong to Gleason patterns 3, 4 and 5 were 
subsequently computed. A.I. risk scores were computed by fitting a Cox regression model using 
these case-level Gleason pattern percentages as input, and the right-censored outcomes as the 
events. This approach was pursued first (rather than direct mapping of %GPs to GG as done by 
pathologists) due to the prognostic importance of precise Gleason pattern quantitation39, as well 
as the exhaustive nature of A.I. grading that rarely leads to classifications of GG1 (e.g. 100% 
GP3) and GG4 (e.g. 100% GP4). Sensitivity analyses evaluating additional ways of obtaining 
risk groups from %GPs, including direct mapping of %GPs to GG and a temporal-split 
methodology, demonstrated qualitatively similar results and are presented in Supplementary 
Table S5. 
 
Gleason pattern 3 percentage was dropped as an input feature to avoid linear dependence 
between features. Leave-one-case-out cross-validation was used to adjust for optimism, similar 
to the 10-fold cross validation used in Epstein et al.14 A.I. risk groups were derived from the A.I. 
risk scores by discretizing the A.I. risk scores to match the number and frequency of pathologist 
GG in validation set 2.  
Statistical Analysis 
Primary and secondary analyses were prespecified and documented prior to evaluation on the 
validation sets. The primary analysis consisted of the comparison of c-indices for DSS between 
pathologist GG and the A.I. risk scores (Table 2). The secondary analysis consisted of the 
comparison between c-indices for pathologist GG and the discretized A.I. risk groups. All other 
analyses were exploratory. 
 
The prognostic performance of the pathologist GG, the A.I. risk scores and the A.I. risk groups 
were measured using Harrel’s C-index40, a generalization of area under the receiver operating 
characteristic curve (AUC) for time-censored data. Confidence intervals for both the c-index of 
A.I. and pathologists, and the differences between them, were computed via bootstrap 
resampling41 with 1000 samples. 
 
In Kaplan-Meier analysis of the pathologist GG and A.I. risk groups, the multivariate log-rank 
test was used to test for differences in survival curves across groups. All survival analysis were 




This study utilized archived anonymized pathology slides, clinicopathologic variables, and 
outcomes from the Institute of Pathology and the Biobank at the Medical University of Graz. 
Interested researchers should contact K. Z. to inquire about access to Biobank Graz data; 
requests for non-commercial academic use will be considered and require ethics review prior to 
access. 
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Figure 1. Kaplan-Meier curves for A.I. and pathologist. Kaplan-Meier (KM) curves for (A) A.I. 
risk groups on validation set 1, (B) A.I. risk groups on validation set 2 and (C) pathologist Grade 






















Table 1. Cohort characteristics. Validation set 1 contains all prostatectomy cases from the 
Biobank Graz between 1995-2014. Validation set 2 is a subset of validation set 1 and contains 
all prostatectomy cases between 2000-2014 where a diagnostic Grade Group was recorded. 
 
 Validation Set 1 Validation Set 2 
Number of cases 2,807 1,517 
Number of slides 83,645 47,626 
Overall survival (OS) 
Median years of follow-up 
(interquartile range) 
13.1 (8.5, 17.2) 11.2 (7.4, 15.2) 
  Censored 2150 1306 
  Observed 657 211 
Disease-specific survival (DSS) 
  Censored 2,673 1,464 
  Observed 134 53 
Grade Group 
  1 611 608 
  2 476 473 
  3 224 224 
  4 128 127 
  5 85 85 
  Unknown 1283 0 
Pathologic T-stage 
  T2 1,640 1,113 
  T3 791 366 
  T4 25 6 
  Unknown 351 32 
Age at diagnosis 
  <60 952 537 
  60-70 1546 817 
  >70 309 163 
Margin status 
  Negative 448 153 
  Positive 242 96 





Table 2. C-Index for pathologist and A.I. grading. The A.I. risk score (B) is a continuous risk 
score from a Cox regression fit on Gleason pattern percentages from the A.I.. The A.I. risk 
group (C) is a discretized version of the A.I. risk score. The discretization was done to match the 
number and frequency of pathologist Grade Groups in validation set 2. In validation set 2, the c-
index for the A.I. risk score was statistically significantly higher than that for the pathologists’ 
Grade Group (p<0.05, prespecified analysis). Bold indicates the highest value in each column 
(dataset). 
 
 C-index [95%CI] 
 Validation Set 1  Validation Set 2 
A) Pathologist Grade Groups N/A* 0.79 [0.71, 0.86] 
B) A.I. risk score (continuous) 0.84 [0.80-0.87] 0.87 [0.81, 0.91]  
C) A.I. risk groups (discretized) 0.82 [0.78-0.85] 0.85 [0.79, 0.90] 
*Not available because pathologist Grade Groups were not available for all cases in validation 






Prostatic Tissue Segmentation Model 
In order to collect data for model development, pathologists were asked to coarsely outline 
extraprostatic tissue and seminal vesicle regions across 221 slides from The Cancer Genome 
Atlas43 and previously-digitized de-identified slides from the Naval Medical Center San Diego8. 
Extraprostatic tissue and seminal vesicle annotations were combined into a single 
‘Extraprostatic Tissue’ class. An additional 150 de-identified slides were randomly sampled from 
the Gleason grading dataset (see “Gleason Grading Model” in the Methods), and any benign or 
Gleason pattern 3, 4, or 5 annotation was considered to be part of the ‘Prostatic Tissue’ class.  
 
The resulting 371 slides were randomly split into a training and tuning split. A convolutional 
neural network, using the same architecture, training methodology, and hyperparameter tuning 
methodology described for the Gleason Grading model, was trained for the binary 
‘Extraprostatic Tissue’ vs. ‘Prostatic Tissue’ task, with a resulting AUC of 0.99 on the tuning set. 
The threshold for binarization was chosen to achieve 97% precision (at 84% recall) of prostatic 
tissue.  
Pathologist Cohort 
Manual pathologist reviews for slides’ stain and tissue types were performed by a cohort of 19 
US board-certified pathologists across 11 states and 2 non-US trained pathologists. The median 





Supplementary Table S1. Hazard ratios for pathologist Grade Group and A.I. risk group 
Hazard ratios from univariable Cox regression models for pathologist Grade Group and A.I. risk 
groups. P-values were computed from a Wald test.  
 
 Validation Set 1 Validation Set 2 
 Hazard ratio [95%CI] P-value Hazard ratio [95%CI] P-value 
Pathologist Grade Group  
  1 
* N/A 
1.0 (reference) - 
  2 3.85 [1.39, 10.70] p=0.010 
  3 4.68 [1.49, 14.76] p=0.009 
  4 14.30 [5.03, 40.62] p<0.001 
  5 35.87 [13.00, 98.97] p<0.001 
A.I. risk group 
1 1.0 (reference) - 1.0 (reference) - 
2 2.83 [1.34, 5.98] p=0.006 0.71 [0.17, 2.97] p=0.641 
3 9.55 [4.70, 19.37] p<0.001 6.23 [2.19, 17.69] p<0.001 
4 13.99 [6.77, 28.92] p<0.001 13.16 [4.74, 36.54] p<0.001 
5 39.96 [20.04, 79.69] p<0.001 35.54 [13.26, 95.27] p<0.001 
*Not available because pathologist Grade Groups were not available for all cases in validation 




Supplementary Table S2. Hazard ratios for A.I. Gleason pattern percentages. Hazard ratios 
from multivariable Cox regression models on A.I. Gleason pattern percentages. Gleason pattern 
percentages from pathologists were not available from the clinical reports for these cohorts. 
Hazard ratios represent the risk increase per 10 percentage point increase in the respective 
pattern. P-values were computed from a Wald test.  
 
 Validation Set 1 Validation Set 2 
 Hazard ratio 
[95%CI] 
P-value Hazard ratio 
[95%CI] 
P-value 
  % Gleason Pattern 3 1.0 (reference) - 1.0 (reference) - 
  % Gleason Pattern 4 1.48 [1.37, 1.60] <0.001 1.58 [1.39, 1.79] <0.001 




Supplementary Table S3. 10-year disease-specific survival rates for disagreements 
between pathologist and A.I.. Kaplan-Meier estimates of 10-year survival rates for validation 
set 2 cases. For each pathologist Grade Group (GG) survival rates are shown for all cases 
(“All”), cases where the A.I. risk group was lower than the pathologist GG (“Lower”), cases 
where the A.I. risk group was the same as the pathologist GG (“Same”) and cases where the 
A.I. risk group was higher than the pathologist GG (“Higher”). Numbers in square braces 






A.I. risk group 
Lower Same Higher 
Grade Group 1 1.00 [0.99, 1.00] 
n=608 
N/A 1.00 [1.00, 1.00] 
n=327 
0.99 [0.97, 1.00] 
n=281 
Grade Group 2 0.98 [0.96, 0.99] 
n=473 
1.00 [1.00, 1.00] 
n=212 
0.98 [0.94, 1.00] 
n=179 
0.93 [0.84, 0.97] 
n=82 
Grade Group 3 0.99 [0.95, 1.00] 
n=224 
1.00 [1.00, 1.00] 
n=117 
0.98 [0.87, 1.00] 
n=56 
0.97 [0.81, 1.00] 
n=51 
Grade Group 4 0.92 [0.83, 0.96] 
n=127 
1.00 [1.00, 1.00] 
n=83 
0.81 [0.56, 0.93] 
n=26 
0.72 [0.33, 0.91] 
n=18 
Grade Group 5 0.83 [0.70, 0.90] 
n=85 
0.93 [0.74, 0.98] 
n=53 






Supplementary Table S4. Sensitivity analysis for years included in validation set 2. All 
results represent C-index with 95% confidence intervals in square braces. The middle column 
presents the original validation set 2 analysis comprising all cases with a Gleason score from 
2000 onwards; the rightmost column presents analysis comprising all cases with a Gleason 
score (including those before 2000). 
 
Year of analysis 2000-2014 1995-2014 
No. of cases 1,517 1,524 
Pathologist Grade Groups 0.79 [0.71, 0.86] 0.78 [0.71, 0.85] 
A.I. risk score 0.87 [0.81, 0.91]  0.86 [0.81, 0.91]  




Supplementary Table S5. Sensitivity analysis for discretization method. Sensitivity 
analysis evaluating different ways of obtaining discrete A.I. risk groups from A.I. Gleason pattern 
percentages. A) Risk scores from a Cox regression model fit on A.I. Gleason pattern 
percentages were generated via leave-one-out cross-validation (LOOCV) and discretized to 
match the pathologist Grade Group distribution in validation set 2. B) Cases from 1995-2000 
were used to train a Cox regression model on A.I. Gleason pattern percentages. Risk scores 
from this model on validation set 2 were discretized to match the pathologist Grade Group 
distribution in validation set 2. C) A.I. Gleason pattern percentages were mapped to discrete risk 
groups using the same rule-based mapping used by pathologists to determine the Grade Group 
from Gleason pattern percentages44. 
 
 C-index [95%CI] 
 Validation Set 1 Validation Set 2 
A) LOOCV 0.82 [0.78, 0.85] 0.85 [0.79, 0.90] 
B) Temporal split N/A 0.86 [0.80, 0.90] 





Supplementary Table S6. Hyperparameters for training Gleason grading model 
 
 Gleason Grading Model Prostatic Tumor Segmentation 
Architecture Custom TuNAS Architecture10 
L2 Weight Decay: 0.004 
Color 
perturbations 
Saturation delta: 0.80 
Brightness delta: 0.96 
Contrast delta: 0.17 
Hue delta: 0.02 
Learning rate 
schedule 
Exponential decay schedule 
Base rate: 0.0042 
Decay rate: 0.95 
Decay steps: 51,733 steps 
Exponential decay schedule 
Base rate: 0.0001 
Decay rate: 0.90 









Other Image input magnification: 10X (1 
μm/pixel) 
Loss function: softmax cross-entropy 
Batch size: 32 
Image input magnification: 5X (2 
μm/pixel) 
Loss function: softmax cross-entropy 













 Univariable C-index [95%CI] Multivariable C-index [95%CI] 
 Validation Set 1  Validation Set 2 Validation Set 1  Validation Set 2 
Pathologist Grade 
Groups 
N/A* 0.79 [0.71-0.86] N/A* 0.87 [0.83-0.91] 
A.I. risk score 
(continuous) 
0.83 [0.80-0.87] 0.87 [0.81-0.91]  0.85 [0.82-0.88] 0.90 [0.85-0.94] 
A.I. risk groups 
(discretized) 
0.82 [0.78-0.85] 0.85 [0.79-0.90] 0.83 [0.79-0.86] 0.90 [0.86-0.93] 

















(B) A.I. Risk Groups within Pathologic T-
Stage 1-2 Cases
 
(C) A.I. Risk Groups within Pathologic T-
Stage 3-4 Cases: 
 
Supplementary Figure S2. Multivariable and subgroup analyses involving pathologic T-
stage. (A) C-indices provided by univariable and multivariable Cox regression models, where 
multivariable regression utilized Grade Group and T-Stage. T-stage was categorized as 1-2, 3-4 
(See Table 1), and multivariable Cox regression was fit with an L2 penalty of 0.02 to assist with 
convergence. (B-C) Kaplan-Meier curves for A.I. risk groups within pathologic T-stage 
categories of 1-2 and 3-4 for validation set 1 
